House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Nov. 14 released preliminary guidance to states on implementing provider tax provisions in the One Big…
Headline
The House is expected to begin a final vote Nov. 12 on the Senate-backed funding package, bringing a potential end to the government shutdown one step closer.…
Headline
The Senate Nov. 10 passed legislation to fund the federal government that will now head to the House for a vote as early as the evening of Nov. 12, as an end…
Headline
The Senate Nov. 9 took a critical first step toward ending the government shutdown as seven Democrats and Sen. Angus King, I-Maine, joined Republicans to…
Headline
Senate negotiations on a potential funding deal to end the record-long government shutdown are ongoing, and the chamber is likely to continue working through…
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…